Kevin Joseph Curran

This inventor holds 24 USPTO granted patents and 7 published patent applications, plus 3 CIPO patents and 5 EPO patents. Top assignees: Wyeth, Pfizer Corporation, American Home Products Corporation. Active years: 2001-2025.

USPTO Granted Patents = 24 (Patent Applications = 7)

% Patents Active = 87.5

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 11.3

ph-index = 6

Forward Citations = 112(Granted Patents)

Location History:

Nyack, NY (US) (2001 - 2002)
Somerville, MA (US) (2014)
Congers, NY (US) (2011 - 2018)
Somerset, NJ (US) (2016 - 2023)

Company Filing History:

American Home Products Corporation

patents

Years Active: 2001-2025

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12202836 - Bicyclic-fused heteroaryl or aryl compounds (2025-01-21),

2. 11702424 - Bicyclic-fused heteroaryl or aryl compounds (2023-07-18),

3. 10793579 - Bicyclic-fused heteroaryl or aryl compounds (2020-10-06),

4. 10329302 - Bicyclic-fused heteroaryl or aryl compounds (2019-06-25),

5. 10022381 - Triazine compounds as PI3 kinase and mTOR inhibitors (2018-07-17),

6. 9879022 - Bicyclic-fused heteroaryl or aryl compounds (2018-01-30),

7. 9458168 - Bicyclic-fused heteroaryl or aryl compounds (2016-10-04),

8. 9174963 - Triazine compounds as PI3 kinase and MTOR inhibitors (2015-11-03),

9. 8859542 - Triazine compounds as PI3 kinase and mTOR inhibitors (2014-10-14),

10. 8835429 - Pyrimidine compounds, their use as mTOR kinase and Pl3 kinase inhibitors, and their syntheses (2014-09-16),

11. 8748421 - Triazine compounds as P13 kinase and MTOR inhibitors (2014-06-10),

12. 8575159 - Triazine compounds as PI3 kinase and mTOR inhibitors (2013-11-05),

13. 8445486 - Triazine compounds as PI3 kinase and mTOR inhibitors (2013-05-21),

14. 8217036 - Triazine compounds as PI3 kinase and mTOR inhibitors (2012-07-10),

15. 8129371 - Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors (2012-03-06),

Title: Kevin Joseph Curran: Innovator in Pharmaceutical Chemistry

Introduction

Kevin Joseph Curran is a distinguished inventor based in Congers, NY, known for his significant contributions to pharmaceutical chemistry. With a remarkable portfolio comprising 24 patents, Curran has made substantial advancements in the formulation and treatment of various medical conditions through innovative compounds.

Latest Patents

Among his latest inventions are the bicyclic-fused heteroaryl or aryl compounds. These compounds encompass tautomers and pharmaceutically acceptable salts with unique structures as defined in his patent specifications. In one embodiment, these compounds are presented in a liquid dosage form that includes a therapeutically effective amount as an adjuvant alongside a therapeutic agent. Additionally, Curran has disclosed associated pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates that enhance the efficacy of these compounds in treating disorders.

Career Highlights

Throughout his career, Curran has worked with prestigious organizations such as Wyeth and Pfizer Corporation. His tenure at these companies has allowed him to collaborate with leading experts in the field and to contribute to the landscape of pharmaceutical innovation.

Collaborations

Notable collaborations in his career include partnerships with colleagues Christoph Martin Dehnhardt and Arie Zask. These collaborative efforts have not only advanced Curran's work but have also provided innovative solutions within the pharmaceutical realm.

Conclusion

Kevin Joseph Curran stands out as a prominent inventor dedicated to the progress of pharmaceutical chemistry. His ongoing innovations and extensive patent portfolio underscore his commitment to enhancing medical treatments and advancing scientific research. As he continues to develop new compounds and methods, Curran's work remains pivotal in the quest for better healthcare solutions.